“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments.” Kip Connor, vice president, ophthalmology disease area stronghold leader, Johnson & Johnson
Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts
Key Takeaways
- Johnson & Johnson adds OLN324, a ~41 kDa VEGF/Ang2 bispecific, after phase 1b JADE showed 12-week retreatment freedom comparable to faricimab, positioning for longer durability in wet AMD/DME.
- Blackstone’s $750 million multi-year co-funding shifts late-stage ophthalmology development risk off J&J’s balance sheet in exchange for milestones and single-digit royalties.
J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, leading a set of deals announced in recent days that span ophthalmology, rare blood cancers, antibody-drug conjugate (ADC) technology, and nonviral DNA medicines.¹ Eli Lilly agreed to buy Calytrix Bio for up to $1.5 billion, Novartis licensed OBI Pharma’s ADC conjugation platform, and Seawolf Therapeutics emerged from stealth with $100 million and a Sanofi partnership worth up to $1.2 billion.²˒³˒⁴
What is J&J getting in Ollin?
J&J will acquire Ollin, a clinical-stage company developing therapies for serious eye diseases, for $2.2 billion upfront plus potential regulatory and commercial milestones of up to approximately $1.125 billion.¹ The deal adds OLN324, a phase 3 bispecific antibody that targets vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) in a small protein format, for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).¹ The transaction is expected to close before the end of 2026.¹
OLN324 was discovered by Innovent Biologics, which developed it with Ollin under the code IBI324.⁵ In the head-to-head Phase 1b JADE study against Roche’s VEGF/Ang2 bispecific Vabysmo (faricimab), 82% of patients receiving OLN324 4 mg went 12 weeks without retreatment, compared with 81% of patients receiving faricimab.⁵ The antibody is about 41 kDa and was designed with higher potency and a higher molar dose than faricimab.⁶
“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments,” said Kip Connor, vice president, ophthalmology disease area stronghold leader at J&J.¹
Separately, Blackstone Life Sciences will pay J&J $750 million over multiple years to fully fund OLN324’s phase 3 program, in exchange for regulatory and sales milestones and single-digit royalties.¹ It is Blackstone’s second large pharma co-funding deal in a week, following its agreement to provide Pfizer up to $1.5 billion for the monthly GLP-1 berobenatide.
Why is Lilly buying Calytrix?
Lilly agreed to acquire Calytrix Bio, a privately held developer of therapies for myeloproliferative neoplasms (MPNs), for up to $1.5 billion in cash, including an undisclosed upfront payment and clinical and regulatory milestones.² The deal is Lilly’s 14th acquisition of 2026.⁷
Calytrix’s lead asset is a preclinical biparatopic antibody designed to target both Type 1 and Type 2 mutant calreticulin (mCALR) in essential thrombocythemia (ET) and myelofibrosis.² The company describes mutant CALR as a tumor-specific cell-surface target that could allow a drug to deplete the disease-driving mutant clone while sparing healthy blood cell production.²
“From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF,” said Brad Prosek, president and chief executive officer of Calytrix Bio.² Interest in disease-modifying MPN antibodies is growing, as BioPharm International® reported when
What does Novartis gain from OBI?
Novartis entered a collaboration and license agreement with Taiwan-based OBI Pharma to develop next-generation ADCs with novel payloads using OBI’s platform technologies.³ Novartis gains exclusive worldwide rights to OBI’s related patents and know-how for selected, undisclosed Novartis payload classes, with an option to add more.³ OBI will receive $30 million upfront and is eligible for milestones bringing the total potential deal value above $2 billion, plus tiered royalties.³
OBI’s GlycOBI technology is a glycan-based conjugation approach designed to work with a range of antibodies, linkers, and payloads, and its GlycOBI DUO extension enables dual-payload ADCs.³ “This collaboration supports our ambition to innovate novel therapies,” said Shiva Malek, global head of oncology, biomedical research at Novartis.³
What is Seawolf developing?
San Diego-based Seawolf Therapeutics emerged from stealth with $100 million in seed and Series A funding from investors including Versant Ventures, MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, and CRISPR Therapeutics.⁴ The company also signed a multi-target research collaboration and exclusive license agreement with Sanofi to develop therapies for bleeding disorders and other undisclosed indications, with up to $1.2 billion in milestones plus tiered royalties.⁴
Seawolf’s TRIDENT platform uses lipid nanoparticles to deliver DNA that encodes a therapeutic protein, along with a factor that helps the DNA enter the cell nucleus.⁴ The company says the approach can produce longer-lasting protein expression than RNA-based LNP therapies and, unlike viral gene therapies, can be redosed.⁴ Its lead proprietary program, for metabolic diseases, is advancing toward development candidate selection.⁴
What do the deals signal?
Recent acquisitions and licensing deals return capital to the broader biotech market. In a
References
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology . News release. Johnson & Johnson; November 16, 2026. Accessed November 16, 2026.Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis . News release. Calytrix Bio; November 16, 2026. Accessed November 16, 2026.OBI Pharma signs collaboration and license agreement with Novartis . News release. OBI Pharma; November 16, 2026. Accessed November 16, 2026.Seawolf Therapeutics debuts with $100 million to advance DNA-based therapeutics . News release. Seawolf Therapeutics; November 16, 2026. Accessed November 16, 2026.Innovent’s partner Ollin Biosciences announces final data from randomized head-to-head study of IBI324 compared to faricimab (Vabysmo) in wet age-related macular degeneration and diabetic macular edema . News release. Innovent Biologics; March 31, 2026. Accessed November 16, 2026.- Malhotra V, Ehrlich JS, Liu W, et al.
IBI324/OLN324: A clinical-stage, small-format, higher-potency, high molar dose bispecific VEGF/Ang-2 inhibitor . Invest. Ophthalmol. Vis. Sci. 2025;66(8):5970. ARVO Annual Meeting abstract. June 2025. Accessed November 16, 2026. - LaHucik K.
Lilly’s 14th acquisition of the year is a little-known blood cancer biotech . Endpoints News. Published November 16, 2026. Accessed November 16, 2026.
Related to this article









